A working group of thoracic pathologists has issued a statement on optimizing tissue stewardship in non-small cell lung cancer. The statement aims to support molecular characterization and treatment selection, but its specifics and potential impact are unclear. Reports on biomarker testing in cancer patients suggest it remains underused, particularly in those with advanced cancer, although comprehensive genomic profiling may enable more precise diagnosis and treatment strategies.